News

AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- Equity Insider News Commentary…

6 months ago

Neurophet to Participate in SNMMI 2025: Showcasing ‘Neurophet SCALE PET’ and Expanding Global Partnerships

Showcasing brain imaging analysis solutions such as Neurophet SCALE PET, which provides SUVR values for PET tracersEngaging in partnering discussions…

6 months ago

Aflac Incorporated Discloses Cybersecurity Incident

COLUMBUS, Ga., June 20, 2025 /PRNewswire/ -- On June 12, 2025, Aflac Incorporated (NYSE: AFL) identified suspicious activity on our network…

6 months ago

13 Press Releases You Need to See This Week

Including the launch of two Netflix Houses, TI's $60B semiconductor investment,Americans' favorite road trip snacks and the debut of Trump…

6 months ago

Biomarkers and New Therapeutic Strategies to Better Treat Brain Cancer

INRS Professor receives $1.2M to advance glioblastoma research  LAVAL, QC, June 20, 2025 /CNW/ - Professor Maya Saleh, a world-renowned expert in…

6 months ago

EssilorLuxottica and Meta to launch Oakley Meta, creating a new category of Performance AI glasses for athletes and fans alike

EssilorLuxottica and Meta to launch Oakley Meta, creating a new category of Performance AI glasses for athletes and fans alike…

6 months ago

INVO Fertility Reminds Shareholders to Cast Their Vote for Upcoming Annual Meeting of Shareholders to be held on Wednesday, June 25, 2025 at 12:00 p.m. Eastern Time

SARASOTA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare…

6 months ago

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusibCHICAGO and FORT…

6 months ago

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent…

6 months ago

Safety Shot Provides Update on Expected Closing of Yerbaé Brands Corp. Acquisition

SCOTTSDALE, AZ, June 20, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today provided…

6 months ago